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Omitted and unjustified medications in the discharge summary
Abstract
BACKGROUND: Limited information exists in regard to drug omissions and unjustified medications in
the hospital discharge summary (DS). OBJECTIVE: To evaluate the incidence and types of drug
omissions and unjustified medications in the DS, and to assess their potential impact on patient health.
METHODS: A prospective observational review of the DSs of all patients discharged from our Internal
Medicine Department over a 3-month period. Data assessment was made by internists using a structured
form. RESULTS: Of the 577 evaluated DSs, 66% contained at least one inconsistency accounting for a
total of 1012 irregularities. There were 393 drug omissions affecting 251 patients, 32% of which were
potentially harmful. Seventeen per cent of all medications (619/3691) were unjustified, affecting 318
patients. The unjustified medication was potentially harmful in 16% of cases, occurred significantly
more frequent in women than in men (61% vs 50%; p = 0.008) and increased linearly with the number
of drugs prescribed (p<0.001). Drug omission had a twofold higher potential to cause harm than
unjustified medication. CONCLUSIONS: Drug omissions and unjustified medications are frequent, and
systemic changes are required to substantially reduce these inconsistencies.
doi: 10.1136/qshc.2007.024588
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ABSTRACT
Background: Limited information exists in regard to drug
omissions and unjustified medications in the hospital
discharge summary (DS).
Objective: To evaluate the incidence and types of drug
omissions and unjustified medications in the DS, and to
assess their potential impact on patient health.
Methods: A prospective observational review of the DSs
of all patients discharged from our Internal Medicine
Department over a 3-month period. Data assessment was
made by internists using a structured form.
Results: Of the 577 evaluated DSs, 66% contained at
least one inconsistency accounting for a total of 1012
irregularities. There were 393 drug omissions affecting
251 patients, 32% of which were potentially harmful.
Seventeen per cent of all medications (619/3691) were
unjustified, affecting 318 patients. The unjustified
medication was potentially harmful in 16% of cases,
occurred significantly more frequent in women than in
men (61% vs 50%; p = 0.008) and increased linearly with
the number of drugs prescribed (p,0.001). Drug
omission had a twofold higher potential to cause harm
than unjustified medication.
Conclusions: Drug omissions and unjustified medications
are frequent, and systemic changes are required to
substantially reduce these inconsistencies.
The discharge summary (DS) is a summation of a
patient’s hospital stay and an essential tool for
relaying relevant information about a patient
when that patient is discharged or transferred to
another department or hospital. The list of all
diagnoses and prescribed drugs is an important
aspect of the DS, since subsequently involved
physicians may base future actions upon it.
Prescription errors are frequent in both inpati-
ent1 and outpatient treatment,2 with about 9% of
these errors resulting in adverse drug events
(ADE).1 However, the real rate of ADE is difficult
to establish, as they are generally poorly documen-
ted in the medical record.3 Thirteen per cent of all
patients experience an ADE within the first month
following hospital discharge.4 The consequences of
ADEs range from minor complaints to unnecessary
treatment/hospitalisation or even disability or
death.5 Furthermore, ADEs result in a considerable
financial burden to society.6 7
Few studies have analysed the occurrence of
inaccurate documentation of medications on dis-
charge.8–10 One of these also reported unjustified
prescriptions,10 but to our knowledge no studies
have examined the frequency or impact of omitted
medications on patients. These inconsistencies or
gaps in documentation may be critical for the
patient, as forgotten or unnecessary pharmacological
therapy may entail inaccurate prophylaxis or treat-
ment of diseases, or provoke preventable ADEs.
We therefore reviewed the DSs of all patients
discharged from our Internal Medicine Department
over a 3-month period in order to: (1) ascertain the
accuracy and consistency of prescription lists, (2)
quantify omitted and unjustified medications, and




This prospective, observational study was per-
formed in the General Internal Medicine
Department of a regional teaching hospital in
southern Switzerland. Our protocol and methods
were approved by the hospital Ethics Committee.
The DSs of consecutive patients discharged
between December 2005 and February 2006 were
eligible for inclusion; we excluded those who died
during hospitalisation (no discharge medications).
Data sources and collection methods
The DSs were reviewed using a structured form,
developed previously for this study. Following pilot
testing during which four physicians analysed 20
DSs each, we refined the form and selected review
criteria. Evaluation of each DS was carried out after
it had been signed by the involved physicians and
sent to the general practitioner. The data collection
then proceeded in two steps (see data quality
assurance); the initial step served for assessment of
accuracy between reviewers, allowing for determi-
nation of k-statistics. We assessed: (1) general
patient information; (2) relevant diagnoses (ie,
requiring a therapy during/after hospitalisation or
requiring a change in medication; and (3) incon-
sistencies between relevant diagnoses and pharma-
cological therapy (omitted and unjustified
medications; see definitions).
Data quality assurance
During the first 2 weeks of the project, two
experienced, board-registered internists indepen-
dently examined the same 40 summaries.
Reliability across reviewers was subsequently
assessed by a third physician and scored utilising
a previous reported scale;11 agreement was deter-
mined to be nearly equivalent for the classification
of unjustified medication (k= 0.85), and substan-
tial for the reviewers’ judgements of diagnoses
implicating drug therapy and diagnoses with drug
omission (k= 0.74 and 0.76, respectively).
Reliability was only moderate for the reviewers’
classification of defendable drug omission
(k= 0.39). Globally, the k value was 0.81. During
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the second step of the review process (10 weeks, 537 DSs), two
internists jointly performed the analysis in order to improve
agreement of low k-values (defendable drug omission). Thus,
differences between the reviewers’ judgements were resolved by
discussion, and a consensus was achieved.
Definitions and classification
Omitted and unjustified medications were defined (table 1) in
accordance to the classification system proposed by Dean et al.12
Assignment of drug omission was based on good clinical
practice retrieved from textbooks,13 14 current recommenda-
tions15 or on-line literature.16 Differentiation between defend-
able and undefendable drug omission (table 1) was achieved by
separate assessement. Medication errors were judged potentially
harmful if the omission or unjustified prescription could have
resulted in increased morbidity/mortality or in an ADE,
respectively. As recommended by Morimoto et al,11 we classified
the unjustified medications with potential for ADE into fatal/
life-threatening, serious or significant.
Statistical analysis
All analyses were carried out with S-Plus 6.2 for Microsoft
Windows. Differences between groups were tested with chi-
square test for contingency tables or two-sided Student t test
for the number of diagnoses or prescribed drugs. A classical
linear regression model was used to determine whether a linear
relationship existed between unjustified medication and the
number of prescribed drugs.
RESULTS
Of 610 patients, 577 were eligible for our study; 33 were
excluded because of intra-hospital death. They had (mean (SD))
4.6 (2.4) relevant diagnoses (3.6 (2.0) diagnoses requiring
medications) and a length of stay of 8.5 (8.6) days. Women in
the study were older than male subjects (69.1 (17.3) vs 64.1
(16.6); p,0.001) and were prescribed more drugs (6.8 (4.2) vs 6.1
(3.5); p = 0.018). Cardiovascular disorders were the most
prevalent discharge diagnoses.
Thirty-four per cent (198/577) of the DSs were error-free. In
the remaining 66% (379/577), a total of 1012 inconsistencies
were identified (table 2); 19% of them were considered
potentially harmful. Patients had, on average, 0.7 drug omis-
sions (0.3 defendable and 0.4 undefendable) and 1.1 unjustified
medications.
We detected 393 drug omissions (table 2); among them, 58%
were not defendable. In 126 cases (32%), the omission had a
potential for harm. The types of diagnoses most frequently
affected by this phenomenon were hypercholesterolaemia in 21
cases (13%), chronic renal failure and psychiatric diseases (14
cases each; 9%), haematological disorders and non-ischaemic
cardiac diseases (11 cases each; 7%), diabetes mellitus and
arterial hypertension (13 cases each; 8%) as well as coronary
heart disease (eight cases; 5%).
Among 3691 prescriptions, 619 (17%) were unjustified
(table 2). Unjustified medication affected 50% of the men and
61% of the women (p = 0.008), and increased significantly
(p,0.001) along with the number of prescribed drugs. Table 3
reports the drug classes most frequently involved in unjustified
therapies. Sixteen per cent of these errors (100 cases concerning
73 patients) were potentially harmful. Unjustified medications
with the potential for significant ADE occurred in 15%, and the
most common drugs identified were acetylsalicylic acid (16
cases), neuroleptic agents (10), antiarrhytmics (7) and anti-
biotics (7). Two unjustified medications were classified as
potentially life-threatening, and an additional five had the
potential for a serious ADE (box 1).
COMMENT
This prospective study was performed in order to quantify the
phenomenon of omitted and unjustified therapy with reference
to the documented diagnoses, as well as to evaluate the possible
consequences of these inaccuracies to the well-being of the
patient.
Table 1 Definitions used for the collection, elaboration and presentation of data
Omitted medication Unintentionally not prescribing a drug for a clinical condition for which medication is indicated; the judgement was based on common
recommendations13–16
Defendable omission Intentional omission, that is, omission justified by a potential and documented contraindication (eg, atrial fibrillation without warfarin
but notation of concurrent peptic ulcer disease)
Undefendable omission Omission without documented contraindication
Potentially harmful omission Omission presumably leading to increased mortality or morbidity (eg, ongoing pneumonia without antibiotics or arterial hypertension
without antihypertensive drug)
Unjustified medication Prescribing a drug for which there is no indication for that patient (not documented corresponding diagnosis)
Potentially harmful unjustified medication A medication which, for a given patient, could have resulted in an ADE
Harmless unjustified medication Largely prescribed and generally well-tolerated medication
Table 2 Incidence of inconsistencies in 577 examined discharge
summaries and corresponding number of potentially harmful cases
Inconsistency Total Severe cases Patients concerned
Unjustified medications 619 100 (16) 318 (55)
Drug omissions 393 126 (32) 251 (44)
Defendable 165 10 (6) 117 (20)
Undefendable 228 116 (51) 162 (28)
Total 1012 226 (22) 379 (66)
Data shown are in absolute values (%).
Table 3 Drug classes implicated in unjustified
medication: 619 cases from 318 patients
Drug classes Cases
Proton-pump inhibitors 142 (45)




Acetylsalicylic acid 27 (8)
Electrolytes 27 (8)
Neuroleptic agents 26 (8)
Antidepressants 23 (7)
Others* 166 (52)
Data shown are in absolute values (percentage of patients
concerned).
*Drug classes concerning ,7% of patients.
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In 66% of all DSs, we found at least one of the studied
inconsistencies. Of the reviewed DSs, 44% were affected by
drug omission, leaving every seventh diagnosis at least partially
without specific pharmacological treatment, and 55% presented
at least one unjustified medication. In general one out of every
six medications was without apparent indication, and women
had significantly more unjustified medications than men, a fact
that partially correlates with the higher number of medications
prescribed to women. Even though undefendable drug omis-
sions occurred nearly three times less frequently than unjusti-
fied medications, they were considered to have a twofold higher
potential for harm.
In nearly half of all the examined DSs, we identified at least
one untreated diagnosis which we believed required a specific
therapy. In most of these cases, no justification for lack of
treatment was provided in the DSs. Although it is plausible
that, in some cases the treatment was not given according to
good clinical judgement, a lack of documentation in itself may
pose a problem. More startlingly, 32% of all omissions were
considered potentially harmful. This is particularly true of
omissions related to hypercholesterolaemia, as we only con-
sidered the cases for which a secondary prophylaxis with a lipid-
lowering drug was clearly indicated.13 14 16 Adjusting for primary
prophylaxis would have considerably increased the result.
Our error rates regarding unjustified medication are slightly
higher than those reported elsewhere.10 However, literature
suggests that the rate of ADE after discharge4 is similar to our
findings (12.5% vs 12.6%). In our study we found only seven
cases of unjustified medications that were considered to have
the potential to cause serious (5) or life-threatening (2) ADEs.
The drugs most often prescribed without proper explanation
were proton-pump inhibitors (PPIs) and benzodiazepines. While
there is some justification for the occasional use of benzodia-
zepines for frequently occurring symptoms such as insomnia or
anxiety, we were surprised by the practice of overprescribing
PPIs; improper use of these medications may not be viewed as
harmful but clearly increases costs.
Our study is in agreement with previous research, generally
confirming that DSs are deficient in all examined fields.8–10 What
makes these papers and our own especially worrisome is that
the accuracy of the data contained in the DSs is often taken for
granted. Strategies to overcome this widespread inadequacy
should rely on the evidenced causes: in our study we principally
revealed inappropriate prescribing and inadequate documenta-
tion in the DSs with a reasonable interdependence of these two
factors in case of unjustified omission/prescription. As reported
elsewhere, medical errors are usually caused by either active
failures (directly attributable to the actions of persons) or latent
conditions (related to the design of systems).17 As these two
types of errors are not mutually exclusive,18 a variety of
corrective actions should be implemented rather than just one
punctual improvement. Both documentation of the DSs and
prescribing of drugs could be improved by a better physician
education, the standardisation of the summary’s format, senior
medical staff editing and database created DS production.
Overall, an unambiguous relationship between diagnoses and
medications should be warranted. Although not proven, it
seems conceivable that better instruction might lead to more
reliable DSs: one survey reported the almost complete lack of
guidance given to junior doctors in preparing them.19 The
implementation of a prescribed dictation template has been
shown to result in better and shorter DSs.20 21 Astonishingly,
Box 1 Unjustified medication with a potential for life-threatening or serious adverse drug events (ADEs)
Potential for life-threatening ADE (n = 2)
c An 83-year-old man with first-degree atrioventricular block and oral anticoagulation for intermittent atrial fibrillation is admitted for
repeated syncopes. Without finding a reversible cause for the latter, he is discharged home with Atenolol 100 mg/day and
Phenprocoumon.
c Potential ADE: syncopes (favoured by Atenelol) with risk of cerebral haemorrhage in case of head traumatism.
c A 77-year-old woman is admitted for reiterated lipothymia. There is no arterial hypertension or chronic heart failure. She has ongoing oral
anticoagulation without any further indication. The diagnostic work up is inconclusive. Discharge with Digoxine, Valsartane and
Phenprocoumon.
c Potential ADE: same as above (Valsartane instead of Atenolol).
Potential for serious ADE (n = 5)
c A 62-year-old woman with oral anticoagulation for intermittent atrial fibrillation is discharged home with Phenprocoumon and
acetylsalicylic acid, the latter without any obvious indication.
c Potential ADE: increased risk for gastro-duodenal haemorrhage (favoured by the synergistic action of the two drugs).
c A 55-year-old man with cerebral metastasis of a lung cancer is admitted for an epileptic attack. He will be discharged home with
acetylsalicylic acid for intermittent atrial fibrillation.
c Potential ADE: increased risk for cerebral haemorrhage.
c A 69-year-old woman, anticoagulated with Phenprocoumon for 3 years after a deep venous thrombosis following total hip replacement is
admitted for anaemia due to gastric ulcer. Therapy with an proton-pump inhibitor is started and anticoagulation temporarily stopped. She
is discharged with Pantoprazole and Phenprocoumon, the latter without any further indication.
c Potential ADE: increased risk for gastro-duodenal haemorrhage.
c An 88-year-old woman with recurrent gastric ulcers is discharged with acetylsalicylic acid, although there is no clear indication for it.
c Potential ADE: increased risk for gastro-duodenal ulcer disease.
c An 86-year-old man is admitted for evaluation of chronic heart failure. He is treated with Amiodarone, for which there is no clear
indication. The diagnostic of hypothyreosis is made and a substitution with levothyroxine initiated, but on discharge Amiodarone has not
been removed.
c Potential ADE: probably reversible hypothyreosis due to Amiodarone.
Error management
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little emphasis is placed in the medical literature on senior staff
editing of the DSs. Peer reviews by senior house officer will
most probably improve the quality and accuracy of these
reports under the condition that they are seriously executed
and—for didactic purposes—adequately discussed with the
junior doctors. However, this review process should be carried
out in a timely fashion, as delays in receipt are strongly criticised
by general practioners.8 Database-generated DS production has
been shown to be superior to other methods in the removal of
systematic errors.22 In fact, by means of an Electronic Medical
Record (EMR) that restructures and optimises the documents of
the previous levels ensuring inter-operability of all documenta-
tion systems, the DSs could be suitably prepopulated. However,
adoption of an electronic health information technology is still
limited,23 perhaps as a consequence of end-user dissatisfaction
with the systems.24 Furthermore, simple strategies, such as clear
discharge instructions to the patient and clear communication
between inpatient and outpatient physicians, are equally
important if harder to systematise.
The major limitation of our study is the inability to connect
the potentially harmful inconsistencies to clinical outcomes. As
the detection of harm due to omitted and unjustified medica-
tions would probably have required prolonged clinical follow-
ups, our hypotheses rely principally on general medical knowl-
edge regarding proven effectiveness of pharmacological therapy/
prophylaxis13 14 16 and the good correlation between our findings
and reported data.4 A second limitation concerns the definitions
as well as the data collection. While our definitions have face
validity, they have not yet been validated by other studies. In
addition, although inter-reviewer reliability was high for
unjustified medications, it was lower for defendable omissions,
reducing the potential usefulness of that subset of data.
Furthermore, during the second phase of data collection, a
minimum of three internists rather than two would probably
have improved assessment when differences in interpretation
arose. Third, the justification for drug omissions and medica-
tions without diagnosis might theoretically have been docu-
mented in other records than the DSs (eg, hospital medical
charts). However, as these supplementary sources are never
forwarded to the general practioner, the appropriatness of the
prescription list can be evaluated exclusively by the DSs, which
by consequence should be edited according to proposed
standards.21 25 26 Finally, there is some uncertainty as to whether
our results may be generalised to other institutions, as both our
patients and reviewers were from a single hospital.
Our study emphasises that drug omissions and unjustified
medications documented in the DSs occur with a high
frequency. Although quite common, the reported inconsisten-
cies were mostly potentially harmless. Future work should seek
to understand the true impact of these errors, and whether
newer initiatives (such as EMR, or medication-reconciliation
efforts) can address these gaps in care.
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